977results about "Tumor specific antigens" patented technology

Compositions of retroviruses and methods of using the same for gene delivery are disclosed, wherein the retroviruses comprise a viral envelope protein comprising at least one mutation that diminishes its native function, a non-viral membrane-bound protein comprising a membrane-bound domain and an extracellular targeting domain.

The invention provides compositions and methods for treating diseases such as cancer. The invention also relates to a method of administering a therapy comprising a chimeric antigen receptor, an IL-15R molecule and an IL-15 molecule.

The invention discloses a GPC3 derived antigen peptide vaccine, an mRNA vaccine, a saRNA vaccine and a preparation method and application thereof. The amino acid sequence of the antigen peptide vaccine is one or any combination of more of amino acid sequences shown as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. According to the invention, an efficient pGPC3 model antigen peptide is screened on the basis of GPC protein, and pGPC3 mRNA and pGPC3 saRNA are designed according to a pGPC3 sequence example. The pGPC3saRNA (at) Lipi vaccine is prepared through a liposome technology, and due to the fact that limiting conditions such as nonapeptide and high-affinity binding with H-2I type molecules (H-2Kb) are adopted during pGPC3 polypeptide antigen screening, APC cells are facilitated to present antigens through an MHCI restrictive pathway, CD8 + T cells are activated, and GPC3 specific CTL is triggered to efficiently kill liver cancer cells. Finally, the pGPC3saRNA (at) Lipi vaccine can completely inhibit the growth of the liver cancer, the inhibition rate reaches 99.8%, and the liver cancer of 4 / 8 mice completely fades down. In addition, the method can be used for vaccine adjuvant and carrier research on a liver cancer subcutaneous transplantation tumor model.

Disclosed herein are compositions of retroviruses and methods of using the same for gene delivery, wherein the retroviruses comprise a viral envelope protein comprising at least one mutation that diminishes its native function, a non-viral membrane-bound protein comprising a membrane-bound domain and an extracellular targeting domain.

The present disclosure relates to targeting moieties such as peptides that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and / or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

Drug delivery nanoparticle compositions and methods for the treatment of a cancer are provided that can be used individually or in combination. These compositions and methods include: (1) exogenous vaccination using neoantigens or tumor-associated antigens to potentiate an anti-tumor immune response; (2) nanoparticle-based drug delivery targeting the liver, aimed at reprogramming the hepatic immune environment to reduce or eliminate tumor antigen tolerance, thereby enhancing the immune system's ability to combat metastatic cancer; and (3) expansion of the liver metastasis treatment platform to target tumor-associated lymphoid structures, supporting the immune response at the primary tumor site. Any of these methods may be optionally combined with chemo-immunotherapy for enhanced efficacy.

Immunogenic targets associated with one or more types of cancer, wherein the immunogenic target includes a shared splicing amino acid-based neoantigen present in any of SEQ ID NOs: 1-2545, or a nucleotide coding therefor, are described, as well as uses thereof, and methods of identifying such immunogenic targets. Particular embodiments relate to immunotherapies for treating a type of cancer, and methods of treating a type of cancer by administering such immunotherapies, wherein the immunotherapy includes an immunogenic target including a shared splicing amino acid-based neoantigen present in any of SEQ ID NOs: 1-2545, or a nucleotide coding therefor.

The present invention provides improved LAMP Constructs comprising specific fragments of the LAMP lumenal domain to deliver cancer antigens to immune cells for enhanced processing. These LAMP Constructs can be used for the treatment of disease and in particular hyperproliferative disorders and / or cancer. The improved LAMP Constructs allow for presentation of properly configured three dimensional epitopes for production of an immune response when administered to a subject. The improved LAMP Constructs can be multivalent molecules, and / or can be provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein can also be used to generate antibodies when administered to a non-human vertebrate.

Compositions of retroviruses and methods of using the same for gene delivery, wherein the retroviruses comprise a viral envelope protein comprising at least one mutation that diminishes its native function, a non-viral membrane-bound protein comprising a membrane-bound domain and an extracellular targeting domain.

Provided herein are nucleic acids, pharmaceutical compositions and vaccines that express a cancer antigen (e.g., PRAME). Also provided herein are methods for treating a cancer.

The invention belongs to the technical field of mRNA vaccines, and particularly relates to a self-replicating mRNA vaccine as well as a preparation method and application thereof. The self-replicating mRNA is transcribed from an alphavirus skeleton vector, the alphavirus skeleton vector comprises gene sequences of alphavirus non-structural proteins nsP2, nsP3 and nsP4 and mutated nsP1, and cysteine at the 492nd position of the mutated nsP1 is mutated into serine. The self-replicating mRNA provided by the invention has higher expression quantity and longer expression time for the target gene. The self-replicating mRNA is used for expressing IMP3 and can be prepared into a vaccine with good prevention and treatment effects on IMP3 positive tumors. Therefore, the invention has a good application prospect in the development of medicines and vaccines.

An antigen peptide is provided specifically for treating individuals suffering from ovarian cancer, preferably based on BRCA1 gene c. 5470_5477del8 mutation. It is selected from amino acid sequences of SEQ ID NO. 1 to SEQ ID NO. 6, or derived by substitution, deletion and / or addition of at least one amino acid. The neoantigen polypeptides of the present disclosure can significantly activate T lymphocytes specific to the BRCA1 gene c. 5470_5477del8 mutation in vitro, stimulating the release of the cytokine IFN-y, indicating notable immunogenicity. This enhances T lymphocytes' ability to target and kill cancer cells from ovarian cancer patients carrying the BRCA1 gene c. 5470_5477del8 mutation. Additionally, the antigen peptide can activate and expand human T lymphocytes specific to the BRCA1 gene c. 5470_5477del8 mutation in vitro for adoptive cell therapy. The antigen peptide of the present disclosure addresses the gap in personalized antigen peptide therapies for ovarian cancer patients with BRCAl-c. 5470_5477del8 somatic mutations.

The present disclosure relates to targeting moieties such as peptides that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and / or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

Disclosed herein are alphavirus vectors that include neoantigen-encoding nucleic acid sequences derived from a tumor of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines.

The invention provides compositions and methods for treating a patient with cancer with an immune cell, e.g., a T-cell, e.g., an engineered T-cell, with increased sialidase activity. The invention also provides compositions and methods for treating a patient with cancer with an immune cell, e.g., a T-cell, e.g., an engineered T-cell, in combination with a sialidase. The invention also provides compositions and methods for treating a patient with cancer with an immune cell, e.g., a T-cell, e.g., an engineered T-cell, pretreated with a sialidase.

This invention relates to modified T cells that inducibly express a bioactive molecule, such as IL-7, and constitutively expresses an antigen receptor, such as a T cell receptor or chimeric antigen receptor that binds to a tumour antigen. The modified T cells may comprise a nucleic acid construct that comprises a first nucleotide sequence encoding the bioactive molecule, a second nucleotide sequence encoding the antigen receptor; an inducible promoter operably linked to the first nucleotide sequence and a constitutive promoter operably linked to the second nucleotide. Nucleic acid constructs and vectors are provided, as well as T cells comprising such constructs and vectors and therapeutic methods and uses thereof.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly ovarian cancer, osteosarcoma, colon cancer, breast cancer, skin cancer, melanoma, esophageal cancer, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESSC), particularly esophageal cancer, or EAC or ESSC.

The present disclosure relates to targeting moieties such as peptides and antibodies that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and / or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

The present disclosure relates to targeting moieties such as peptides and antibodies that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and / or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

The present disclosure provides a composition comprising a nucleic acid sequence encoding from about 1 to about 100 amino acid sequences, the amino acid sequences being tumor-specific antigens wherein at least one tumor-specific antigen is an amino acid sequence associated with the WNT pathway. In some embodiments, the nucleic acid sequence encodes from about 20 to about 60 tumor specific antigens; wherein from about 1 to about 8 tumor specific antigens are selected from one or a combination of the following: WNT, CTNNB1, AXIN1, AXIN2, APC, CK1, and GSK3B. Also provided is a cell comprising any one or more compositions disclosed herein and a pharmaceutical composition comprising: (i) a therapeutically effective amount of one or more compositions as disclosed herein; and (ii) a pharmaceutically acceptable carrier. A method of treating cancer in a subject in need thereof is also provided.

The present disclosure provides T cell modulatory polypeptide-epitope conjugates (T-Cell-MP-epitope conjugates) comprising a chemical conjugation site at which an NY-ESO (e.g., NY-ESO-1 or NY-ESO-2) or a MAGE (e.g., MAGEA4) peptide epitope is covalently attached and at least one immunomodulatory polypeptide sequence that may be variant selected to exhibit reduced binding affinity to its cognate co-immunomodulatory polypeptide. The T-Cell-MP-epitope conjugates are useful for modulating the activity (e.g., increasing proliferation or cytotoxic activity) of T-cells specific to the NY-ESO or MAGE peptide epitope in an epitope selective / specific manner, and accordingly, for treating individuals with, for example, cancers expressing the covalently attached epitope. The disclosure also provides T-Cell-MP-epitope conjugates with targeting sequences that can server to, among other things, localize the T-Cell-MP-epitope conjugates to a specific tissue or cell type.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma.

The present invention provides a T-cell receptor (TCR) which binds to an immunogenic peptide when presented by a major histocompatibility complex (MHC).

The present disclosure provides compositions and methods for targeting a Ras antigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as a T cell receptor or a chimeric antigen receptor, that bind to a Ras antigen:HLA complex. Polynucleotides encoding such binding protein can introduced into a host cell, such as a T cell, and the cell can be used in immunotherapy for treating various cancers. Also provided are immunogenic polypeptides that can be useful to, for example, induce an immune response against a mutated Ras or to identify a binding protein that binds to a Ras antigen.

The present invention relates to an isolated T cell receptor (TCR) specific for MAGE-A4 and a polypeptide comprising a functional portion of the TCR. Further implicated are a multivalent TCR complex, a nucleic acid encoding a TCR, a cell expressing the TCR and a pharmaceutical composition comprising the TCR. The invention also refers to the TCR for use as a medicament, in particular to the TCR for use in the treatment of cancer.

To provide a method for selecting a subject for whom the effect of a pharmaceutical composition for treating or preventing cancer can be expected.SOLUTION: A step of determining an expression level of WT1mRNA using a sample collected from a subject, and a step of providing an indicator that the subject is a subject for whom the pharmaceutical composition is expected to be effective when the expression level of WT1mRNA is less than or equal to or less than 10000 copies / μ gRNA.SELECTED DRAWING: None

The present invention relates to 4-1BB ligand (4-BBL) extracellular domain (ECD) muteins having reduce affinity for its cognate receptor 4-1BB. The 4-1BBL ECD muteins can be present in homo- or heterotrimeric fusion protein comprising three 4-1BBL ECD monomers. The invention further relates conjugates of such the 4-BBL ECD muteins with a heterologous moiety, such as an antigen binding protein. The antigen-binding regions comprised in the antigen binding protein in the conjugates preferably are specific for a tumor-associated antigen (TAA). In addition to a 4-BBL ECD mutein, the conjugates can comprise further NK cell-activating cytokines, such an IL-21 receptor agonist. The conjugates can further comprise an antigen-binding region that has affinity for a surface antigen expressed on NK cells, e.g. CD16A. Alternatively, the conjugates can further comprise an antigen-binding region that specifically binds an epitope of a γδ TCR. The conjugates of the invention specifically redirect and activate NK cells or γδ T cells to lyse targeted tumor cells. The invention further relates to the use of the 4-BBL ECD muteins and conjugates thereof in the treatment of cancer, preferably a cancer expressing the TAA.

The present invention relates to antigen-based immunotherapy, in particular cancer immunotherapy. In particular, the present invention provides an antigen peptide which is different from a fragment of a human tumor antigen but has amino acid similarity to the fragment of the human tumor antigen. The invention also provides immunogenic compounds, nanoparticles, cells and pharmaceutical compositions comprising such antigen peptides and nucleic acids encoding such antigen peptides.

The present disclosure relates to targeting moieties such as peptides and antibodies that can bind to DLL3. The disclosure also provides targeting constructs, which may include a targeting moiety attached, via an optional linker, to a chelating agent for association of a cargo. Methods of making the constructs and formulations thereof are also provided. Methods of using the constructs and / or formulations thereof to treat subjects, for example, to treat or prevent cancer, are also described.

The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.